[go: up one dir, main page]

EP0639275A1 - NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. - Google Patents

NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.

Info

Publication number
EP0639275A1
EP0639275A1 EP93910819A EP93910819A EP0639275A1 EP 0639275 A1 EP0639275 A1 EP 0639275A1 EP 93910819 A EP93910819 A EP 93910819A EP 93910819 A EP93910819 A EP 93910819A EP 0639275 A1 EP0639275 A1 EP 0639275A1
Authority
EP
European Patent Office
Prior art keywords
receptor subtypes
gabaa receptor
compounds
novel
formulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93910819A
Other languages
German (de)
French (fr)
Other versions
EP0639275B1 (en
Inventor
Kenneth Shaw
Alan Hutchison
Andrew Thurkauf
John Tallman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of EP0639275A1 publication Critical patent/EP0639275A1/en
Application granted granted Critical
Publication of EP0639275B1 publication Critical patent/EP0639275B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides methods for screening drug compounds utilizing compounds of formulas (I and II), and the pharmaceutically acceptable salts thereof where: R1, R2, R3, and R4 represent hydrogen, halogen, alkyl or alkoxy substituents; R5 is hydrogen or lower alkyl; X and Y represent hydrogen, halogen, alkyl or alkoxy substituents; and Z is hydrogen or fluorine. The invention also provides tritium or iodine isotope radiolabeled compounds of the formulas (I and II) radiolabeled with tritium or isotopes of iodine. The invention further provides novel GABAa receptor subtypes which specifically bind to compounds of formulas (I or II). The invention also provides GABAa receptor subtypes which are bound in situ to a compound of formula (I or II). The compounds provided herein bind selectively to a novel subtype of the GABAa binding site. Selective interaction of ligands at this unique receptor population results in pharmacological specificity which may lead to superior anxiolytics, cognition enhancers, anticonvulsants and sedative hypnotics.
EP93910819A 1992-04-30 1993-04-30 NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES Expired - Lifetime EP0639275B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US876050 1992-04-30
US07/876,050 US5597920A (en) 1992-04-30 1992-04-30 Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
PCT/US1993/003920 WO1993022681A1 (en) 1992-04-30 1993-04-30 NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES

Publications (2)

Publication Number Publication Date
EP0639275A1 true EP0639275A1 (en) 1995-02-22
EP0639275B1 EP0639275B1 (en) 1997-09-17

Family

ID=25366890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93910819A Expired - Lifetime EP0639275B1 (en) 1992-04-30 1993-04-30 NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES

Country Status (12)

Country Link
US (2) US5597920A (en)
EP (1) EP0639275B1 (en)
JP (1) JPH08500333A (en)
KR (1) KR950702032A (en)
AT (1) ATE158414T1 (en)
AU (1) AU691470B2 (en)
CA (1) CA2134227A1 (en)
DE (1) DE69314024T2 (en)
DK (1) DK0639275T3 (en)
ES (1) ES2110090T3 (en)
GR (1) GR3025698T3 (en)
WO (1) WO1993022681A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
EP0934528B1 (en) * 1996-10-25 2002-09-04 Neurosearch A/S A method for the identification of compounds with anxiolytic potential
CA2371219A1 (en) * 1999-05-07 2000-11-16 Neurogen Corporation Methods for screening gaba-modulatory compounds for specified pharmacological activities
US6737242B1 (en) 1999-05-07 2004-05-18 Neurogen Corporation Methods for screening GABA-modulatory compounds for specified pharmacological activities
RU2340611C2 (en) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Pyrazole derivatives applied as protein kinase inhibitors
ES2242771T5 (en) * 2000-09-15 2011-10-14 Vertex Pharmaceuticals Incorporated PIRAZOL COMPOUNDS USEFUL AS PROTEIN QUINASE INHIBITORS.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1698627A1 (en) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ZA200301703B (en) * 2000-09-15 2004-03-02 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
CN102250071A (en) 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 Pyrazole compounds useful as protein kinase inhibitors
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003257078B2 (en) 2002-08-02 2010-04-01 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of GSK-3
AR056763A1 (en) 2005-11-03 2007-10-24 Vertex Pharma AMINOPIRIMIDINES REPLACED WITH TIAZOL OR PIRAZOL, USEFUL AS ANTICANCER AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NZ580884A (en) 2007-05-02 2012-02-24 Vertex Pharma Thiazoles and pyrazoles useful as kinase inhibitors
AR067762A1 (en) 2007-07-31 2009-10-21 Vertex Pharma PROCESS TO PREPARE 5-FLUORO-1H-PIRAZOLO (3,4-B) PIRIDIN-3-AMINA AND DERIVATIVES OF THE SAME
WO2010027921A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415303A1 (en) * 1978-05-31 1979-08-17 Ferrosan As METHOD FOR DETERMINING THE CONCENTRATION OF BENZODIAZEPINES IN A BODY FLUID
IL90315A0 (en) * 1988-06-01 1989-12-15 Ferrosan As Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
WO1992006094A1 (en) * 1990-10-09 1992-04-16 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of gaba brain receptor ligands
US5130430A (en) * 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
AU4117493A (en) * 1992-04-08 1994-11-21 Neurogen Corporation Certain aryl fused pyrrolopyrimidines; a new class of gaba brain receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9322681A1 *

Also Published As

Publication number Publication date
JPH08500333A (en) 1996-01-16
AU4117793A (en) 1993-11-29
GR3025698T3 (en) 1998-03-31
KR950702032A (en) 1995-05-17
CA2134227A1 (en) 1993-11-11
ATE158414T1 (en) 1997-10-15
AU691470B2 (en) 1998-05-21
WO1993022681A1 (en) 1993-11-11
ES2110090T3 (en) 1998-02-01
US5597920A (en) 1997-01-28
US5688654A (en) 1997-11-18
DE69314024D1 (en) 1997-10-23
DK0639275T3 (en) 1998-04-14
EP0639275B1 (en) 1997-09-17
DE69314024T2 (en) 1998-04-16

Similar Documents

Publication Publication Date Title
EP0639275A1 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
CO4890843A1 (en) IL-8 RECEPTORS ANTAGONISTS OF IL-8
BR0215202A (en) A2b selective pyrimidine antagonist compounds, their synthesis and use
CA2037630A1 (en) Nitrogen-containing heterocylic compounds, their production and use
DK89595A (en) Process for Preparation of 1- (3-Dimethylaminopropyl) -1 '- (4-fluorophenyl) -1,3-dihydroisobenzofuran-5-carbonitrile
AR021533A1 (en) DERIVATIVES OF 2,5-DIAZABICICLO [2.2.1] HEPTANE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
HUP9901245A2 (en) Indole derivatives useful as endothelin receptor antagonists, preparation and use thereof, pharmaceutical compositions containing these compounds
WO1994013658A3 (en) Benzocycloheptenes, benzoxepines and benzothiepines
CA2036618A1 (en) Fused thiophene derivatives, their production and use
GR3023303T3 (en) 5,6-Disubstituted-3-pyridylmethyl ammonium halide compounds useful for the preparation of 5-(substituted methyl)-2,3-pyridinedicarboxylic acids
ATE224T1 (en) 1,2-DIHYDRO-QUINOLINE-2-ONE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND MEDICATIONS CONTAINING THESE COMPOUNDS.
CO5031286A1 (en) CIANO GUANADINA COMPOUNDS AS ANTAGONISTS OF IL-8 RECEPTORS AND PREPARATION METHOD
DK0991640T3 (en) Synthesis of intermediates useful for the preparation of brake-substituted tricyclic compounds
ATE433440T1 (en) UREA LINK COMPOUNDS AND THEIR USE AS PPAR REGULATORS
ATE193700T1 (en) BENZOCYCLOALKENE COMPOUNDS, THEIR PREPARATION AND USE
HUP9801950A2 (en) 2-(arylphenyl-amino)-imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
TR200200125T2 (en) New aminothiazole derivatives, their preparation and pharmaceutical compositions containing them.
SE8503415D0 (en) NOVEL ISOINDOLINYL-ALKYL-PIPERAZINES
SE8500107D0 (en) NEW 8ALFA-ACYLAMINOERGOLINE
DK0383686T3 (en) Carboxyalkyl ethers of 2-amino-7-hydroxytetraline and process for their preparation
ATE44648T1 (en) ANTIHYPERTENSIVE COMBINATION MEDICATION.
ATE102626T1 (en) HETEROCYCLIC COMPOUNDS, THEIR REPRESENTATION AND USE.
WO1999021848A3 (en) Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
ES8401766A1 (en) Azino rifamycins
ATE323085T1 (en) HETEROCYCLIC COMPOUNDS WITH AFFINITY FOR THE HT1 RECEPTOR AND THEIR THERAPEUTIC USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19950221

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 158414

Country of ref document: AT

Date of ref document: 19971015

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69314024

Country of ref document: DE

Date of ref document: 19971023

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2110090

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 76540

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19971212

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19990315

Year of fee payment: 7

Ref country code: GB

Payment date: 19990315

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990322

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19990330

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19990406

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19990407

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19990419

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 19990421

Year of fee payment: 7

Ref country code: IE

Payment date: 19990421

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 19990429

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19990430

Year of fee payment: 7

Ref country code: DE

Payment date: 19990430

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990511

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19990614

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19990726

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000503

BERE Be: lapsed

Owner name: NEUROGEN CORP.

Effective date: 20000430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001031

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001101

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000430

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001229

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20001101

EUG Se: european patent has lapsed

Ref document number: 93910819.7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20001031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20020204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050430